Back to results
US 2013/0078236 A1Published application
Anti-CD28 humanized Antibodies
AssigneesEffimune, Insitut National de la Sante et de la Recherche Medicale (INSERM)
InventorsCaroline Mary, Nicolas Poirier, Bernard Vanhove
Life of this patent
Estimating the term…
Abstract
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Claims11
An anti-CD28 antibody, characterised in that it is selected among:
- (a) an antibody having a CD28-binding site consisting of:
- a first variable domain (also defined herein as the “heavy chain variable domain”) comprising SEQ ID NO:
- 1, wherein said variable domain may optionally further comprise a Q residue at its N-terminal end;
- a second variable domain (also defined herein as the “light chain variable domain”) comprising SEQ ID NO:
- 2, or
- (b) an antibody having a CD28-binding site consisting of:
- a first variable domain having the CDRs of the variable domain of SEQ ID NO:
- 1;
- a second variable domain having the CDRs of the variable domain of SEQ ID NO:
- 2.
7 more elements
Dependencies are inferred from the claim text.